KALA BIO, INC. Stock Split Ratio
KALA BIO, INC. (KALA) had Stock Split Ratio of 2.00% as of 2026-05-08, per its 10-Q filed 2026-08-19.
Financial Statements › Notes › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2026-08-19
- 2026-05-08: Stockholders' Equity Note, Stock Split, Conversion Ratio 2.00%.
- 2022-10-20: Stockholders' Equity Note, Stock Split, Conversion Ratio 2.00%.
- 2017-07-07: Stockholders' Equity Note, Stock Split, Conversion Ratio 19.20%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio |
|---|---|
| 2026-05-08 | 2.00% 10-Q · filed 2026-08-19 |
| 2022-10-20 | 2.00% 10-K · filed 2024-03-29 |
| 2017-07-07 | 19.20% 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |